Drugs / carcinoembryonic antigen peptide 1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003434 | Jun 1998 → Aug 2002 | malignant pancreatic neoplasm | Duke University | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carcinoembryonic antigen peptide 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003434 ↗ |
| Known as | CAP-1 | “Objective: I. Perform a pilot study of active immunotherapy with autologous dendritic cells pulsed with the CEA peptide, CAP-1, after surgical resection in patients with CEA...” NCT00003434 ↗ |
| Modality | Peptide | “carcinoembryonic antigen peptide-1” NCT00003434 ↗ |
| Route | Intravenous | “Equal doses of CEA and HBsAg peptide pulsed dendritic cells are administered intravenously over 3 minutes every 4 weeks for a total of 6 doses each.” NCT00003434 ↗ |